Edwards Lifesciences (NYSE:EW) had its price objective reduced by SunTrust Banks to $170.00 in a research note issued to investors on Friday morning, The Fly reports. They currently have a buy rating on the medical research company’s stock. SunTrust Banks also issued estimates for Edwards Lifesciences’ Q3 2018 earnings at $1.02 EPS, Q3 2019 earnings at $1.20 EPS and FY2022 earnings at $7.20 EPS.

Other equities analysts have also recently issued reports about the stock. ValuEngine raised shares of Edwards Lifesciences from a hold rating to a buy rating in a report on Monday, May 7th. Zacks Investment Research raised shares of Edwards Lifesciences from a hold rating to a buy rating and set a $165.00 price objective on the stock in a research note on Saturday, July 14th. Guggenheim reissued a buy rating and issued a $170.00 price objective on shares of Edwards Lifesciences in a research note on Friday, July 27th. Jefferies Financial Group reissued a buy rating and issued a $168.00 price objective on shares of Edwards Lifesciences in a research note on Friday, July 27th. Finally, Northland Securities reissued a hold rating and issued a $120.00 price objective on shares of Edwards Lifesciences in a research note on Friday, July 27th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $152.45.

Shares of Edwards Lifesciences stock opened at $137.11 on Friday. The firm has a market capitalization of $28.91 billion, a PE ratio of 36.24, a price-to-earnings-growth ratio of 2.01 and a beta of 0.60. Edwards Lifesciences has a 12 month low of $100.20 and a 12 month high of $156.87. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.47 and a current ratio of 1.86.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 26th. The medical research company reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $972.00 million for the quarter, compared to analysts’ expectations of $968.32 million. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.08 EPS. equities research analysts expect that Edwards Lifesciences will post 4.66 EPS for the current fiscal year.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction on Thursday, May 17th. The shares were sold at an average price of $135.88, for a total transaction of $4,470,452.00. Following the sale, the chief executive officer now directly owns 112,731 shares in the company, valued at approximately $15,317,888.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Catherine M. Szyman sold 9,815 shares of the business’s stock in a transaction on Thursday, May 24th. The stock was sold at an average price of $139.39, for a total transaction of $1,368,112.85. Following the sale, the vice president now owns 20,012 shares in the company, valued at $2,789,472.68. The disclosure for this sale can be found here. Insiders sold a total of 193,515 shares of company stock worth $27,523,945 over the last three months. 1.84% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. HighPoint Advisor Group LLC boosted its position in shares of Edwards Lifesciences by 38.0% during the 1st quarter. HighPoint Advisor Group LLC now owns 2,897 shares of the medical research company’s stock worth $414,000 after purchasing an additional 798 shares in the last quarter. CIBC Private Wealth Group LLC boosted its position in shares of Edwards Lifesciences by 7.2% during the 2nd quarter. CIBC Private Wealth Group LLC now owns 995,781 shares of the medical research company’s stock worth $144,956,000 after purchasing an additional 66,544 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its position in shares of Edwards Lifesciences by 269.6% during the 1st quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 37,374 shares of the medical research company’s stock worth $5,090,000 after purchasing an additional 27,261 shares in the last quarter. Global Financial Private Capital LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth $624,000. Finally, Fulcrum Capital LLC purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $2,920,000. Institutional investors own 81.53% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Article: Short Selling Stocks, A Beginner’s Guide

The Fly

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.